When AVAC was founded in 1995, we were called the AIDS Vaccine Advocacy Coalition. Our singular goal was to advance swift, ethical research for a vaccine that was then—and is today—essential to bring the epidemic to a conclusive end.

Twenty years later, AVAC is still focused on swift and ethical research, but our scope has expanded. Along with vaccines, we advocate for PrEP, microbicides, voluntary medical male circumcision, and more. And we’ve evolved with the field. As positive results have delivered new tools, AVAC has led the charge for the rapid, strategic rollout of all options needed to end the epidemic.

Through it all, our message has been the same: prevention is the center of the AIDS response. Not just any prevention but smart, evidence-based, community-owned, rights-based strategies.

AVAC is the only advocacy group working across the full spectrum of biomedical prevention interventions, from early-stage research to large-scale rollout.

We do this work because it’s essential. We are able to do it because of our robust partnerships worldwide. We will keep doing it—with your help—until the epidemic has, finally, come to an end.

AIDS VACCINES, HIV PREVENTION AND THE GLOBAL EPIDEMIC: A TIMELINE

- First US government trial held of preventive vaccine candidate
- The AIDS Service Organization (TASO) established in Uganda
- International Community of Women Living with HIV/AIDS founded
- First phase II AIDS vaccine trial begins, of two gp120 products
- Female condom receives approval from US FDA
- US Congress requires NIH and other agencies to expand involvement of women and minorities in all research
- US Public Health Service recommends AZT for pregnant women with HIV to reduce onward transmission
- First major syringe exchange program opens in the US
- 1987
- 1988
- 1992
- 1993
- 1994

TWO DECADES, ONE MESSAGE: PREVENTION MATTERS
We’ve experienced 20 years of breakthroughs and disappointments in prevention research. A vaccine that many had given up on was the first to provide modest protection. One microbicide everyone hoped for didn’t pan out. Male circumcision and PrEP studies overcame skepticism and, together with antiretroviral therapy, paved the way for a prevention revolution. Through it all, AVAC has worked with partners to maintain the field’s focus and press for continued research into an AIDS vaccine, a cure and more.
When AVAC was founded, the only biomedical HIV prevention options for adults were male and female condoms. The pathway for introducing any new strategy was largely unmapped. No one knew where the gaps would be—between trial result and country action, between guidance and financial support. Now we do. Over two decades, AVAC has not only identified the gaps; we’ve worked to bridge them, so that products reach people in programs that work—without delay.

Research to Rollout: A schematic road map

For the first decade of AVAC’s existence, most prevention advocacy focused on actions to the left of the red arrow above. But with results, come new challenges. We now work on research and on ensuring products cross the gap between efficacy and real-world use.
CREATING A GLOBAL NETWORK OF PREVENTION ADVOCATES.

Twenty years ago, advocacy for HIV prevention hardly existed. So AVAC helped build a global network of advocates equipped with effective advocacy strategies and the latest evidence. With our support, they are putting prevention on the agenda in countries and communities around the globe.

Partnering for a Prevention Revolution

Through Advocacy Fellows, PxROAR members, coalition-building, strategic convening, training and other support, AVAC partners with stakeholders throughout the world to increase awareness and understanding of the current state of HIV prevention research and implementation. Together, we hold decision-makers accountable and press for smart investments and sound policies in all aspects of HIV prevention.
When the world lacked a plan for ending AIDS, we helped create one. Now we’re holding global leaders accountable for results—demanding the resources, policies and evidence-based plans needed to deliver all of today’s prevention options to the people who need them, and to plan for the rapid rollout of new options as they emerge.

**DEMANDING ACTION ON AN AGENDA TO END AIDS.**

A Three-Part Agenda for Ending AIDS

**DEMONSTRATE** and roll out new HIV prevention options

**DEVELOP** long-term solutions needed to end the epidemic

**DELIVER** proven tools for immediate impact

**GOAL:** A sustained decline in HIV infections

Years to impact

Zero to 5  5 to 10  10 to End

---

- **CAPRISA 004 trial of Tenofovir gel shows modest efficacy in South African women**—first for microbicides
- **iPrEx trial shows efficacy of daily oral PrEP in gay men and transgender women**
- **Pox Protein Public-Private Partnership (P5) established to build on results of RV144**
- **US FDA approves daily Truvada as oral PrEP**
- **Analysis of RV144 results reveals two correlates of risk in participants**
- **Hundreds of broadly neutralizing antibodies identified as possible targets for vaccine development**
- **HPTN 052 trial shows treatment can reduce risk of transmission by up to 96%**
- **Partners PrEP trial shows high efficacy of daily oral PrEP in HIV-negative men and women in serodiscordant couples**

---

**RV144 trial of ALVAC/AIDSVAX shows modest 31.2% efficacy in preventing HIV acquisition**—first evidence of efficacy in any AIDS vaccine clinical trial

**HVTN 505 trial of DNA prime/Ad5-boost vaccine begins**

**South Africa begins massive expansion of ART program**
Communities’ support for prevention research can never be taken for granted—it has to be earned. For 20 years, we’ve helped build trust between researchers, funders and communities to speed the ethical development and rollout of new prevention options. And when controversy threatened to derail those efforts, AVAC provided leadership and resources to help get them back on track.

The Good Participatory Practice (GPP) Guidelines provide trial funders, sponsors and implementers with systematic guidance on how to effectively engage with all stakeholders in the design and conduct of biomedical HIV prevention trials.
Your gift to AVAC will support our efforts to accelerate the development and delivery of HIV prevention options to men and women worldwide. With your help, we can continue to convene, collaborate and communicate a strong, clear and cohesive vision for HIV prevention today, tomorrow and to end the epidemic.

It will take all of us working together to end AIDS. Please join us.

To learn more about AVAC, including our history, our focus and our team, please visit www.avac.org. And to support this work, please go to www.avac.org/donate.